TABLE 1.
Characteristics of COVID‐19 infected patients with and without malignancy
| Malignancy | P‐value | |||
|---|---|---|---|---|
| No | Yes | |||
| Demographic data | ||||
| Age [median, year] | 57 | 62 | .078 | |
| Gender | Male | 56 (60.2%) | 55 (59.8%) | .952 |
| Female | 37 (39.8%) | 37 (40.2%) | ||
| Comorbidity | 50 (53.8%) | 33 (35.9%) | .014 | |
| Number of comorbidities | 0 | 43 (46.2%) | 59 (64.1%) | .064 |
| 1 | 25 (26.9%) | 20 (21.7%) | ||
| 2 | 18 (19.4%) | 7 (7.6%) | ||
| 3 | 6 (6.5%) | 6 (6.5%) | ||
| 4 | 1 (1.1%) | 0 | ||
| Diabetes mellitus | 30 (32.3%) | 14 (15.2%) | .006 | |
| Hypertension | 28 (30.1%) | 17 (18.5%) | .065 | |
| IHD/CHF | 14 (15.1%) | 14 (15.2%) | .975 | |
| COPD | 4 (4.3%) | 1 (1.1%) | .187 | |
| Asthma | 2 (2.2%) | 0 | .251 | |
| CKD/ESRD | 4 (4.3%) | 2 (2.2%) | .346 | |
| Hepatitis B | 0 | 2 (2.2%) | .246 | |
| Deep venous thrombosis | 0 | 1 (1.1%) | .497 | |
| Symptoms | ||||
| Fatigue | 66 (71%) | 66 (71.7%) | .908 | |
| Fever | 60 (64.5%) | 40 (43.5%) | .004 | |
| Chill | 33 (35.5%) | 13 (14.1) | .001 | |
| Malaise | 46 (49.5%) | 28 (30.4%) | .008 | |
| Chest pain | 10 (10.8%) | 10 (10.9%) | .980 | |
| Headache | 9 (9.7%) | 7 (7.6%) | .617 | |
| Seizure | 0 | 5 (5.4%) | .029 | |
| Lack of consciousness | 3 (3.2%) | 15 (16.3%) | .003 | |
| Dry cough | 48 (51.6%) | 24 (26.1%) | .0001 | |
| Productive cough | 17 (18.3%) | 18 (19.6%) | .823 | |
| Shortening of breath | 82 (88.2%) | 73 (79.3%) | .104 | |
| Hemoptysis | 0 | 3 (3.3%) | .079 | |
| Sore throat | 5 (5.4%) | 2 (2.2%) | .227 | |
| Nausea | 21 (22.6%) | 13 (14.1%) | .138 | |
| Vomiting | 16 (17.2%) | 5 (5.4%) | .012 | |
| Diarrhea | 6 (6.5%) | 4 (4.3%) | .747 | |
| Constipation | 1 (1.1%) | 4 (4.3%) | .211 | |
| Gastrointestinal bleeding | 0 | 4 (4.3%) | .059 | |
| Bowel obstruction | 1 (1.1%) | 1 (1.1%) | 1 | |
| Signs | ||||
| Systolic blood pressure | [median, mmHg] | 130 | 120 | .0001 |
| Diastolic blood pressure | [median, mmHg] | 80 | 75 | .0001 |
| Oxygen saturation | ||||
| Normal | 11 (11.8%) | 19 (20.9%) | .383 | |
| O2sat = 90–95% | 41 (41.1%) | 33 (36.3%) | ||
| O2sat = 90–75% | 37 (39.8%) | 35 (38.5%) | ||
| O2sat < 75% | 4 (4.3%) | 4 (4.4%) | ||
| Heart rate | ||||
| Normal | 58 (62.4%) | 60 (65.2%) | .687 | |
| Bradycardia | 0 | 0 | ||
| Tachycardia | 35 (37.6%) | 32 (34.8%) | ||
| Respiratory rate | ||||
| Normal | 9 (9.7%) | 5 (54%) | .275 | |
| Bradypnea | 0 | 0 | ||
| Tachypnea | 84 (90.3%) | 87 (94.6%) | ||
| Temperature | ||||
| Normal | 72 (77.4%) | 81 (88%) | .102 | |
| Hypothermia | 1 (1.1%) | 0 | ||
| Fever | 20 (21.5%) | 11 (12%) | ||
| Laboratory data | ||||
| Neutrophil count | ||||
| Normal | 64 (69.6%) | 45 (48.9%) | .002 | |
| Neutropenia | 1 (1.1%) | 11 (12%) | ||
| Neutrophilia | 27 (29.3%) | 36 (39.1%) | ||
| Lymphocyte count | ||||
| Normal | 25 (26.9%) | 32 (34.8%) | .245 | |
| Lymphopenia | 68 (73.1%) | 60 (65.2%) | ||
| Thrombocytopenia | 7 (7.5%) | 33 (35.9%) | .0001 | |
| Anemia | 20 (21.5%) | 34 (97%) | .021 | |
| Sodium level | ||||
| Normal | 64 (68.8%) | 59 (64.1%) | .239 | |
| Hyponatremia | 28 (30.1%) | 27 (29.3%) | ||
| Hypernatremia | 1 (1.1%) | 6 (6.6%) | ||
| Potassium level | ||||
| Normal | 73 (78.5%) | 68 (74.7) | .335 | |
| Hypokalemia | 18 (19.4%) | 17 (18.7%) | ||
| Hyperkalemia | 2 (2.2%) | 6 (6.6%) | ||
| ESR [mean ± SD, mm/h] | 54.5 ± 5.3 | 63.14 ± 4.8 | .605 | |
| CRP [median, mg/L] | 58.7 | 89.5 | .109 | |
| Cr [median, mg/dL] | 0.9 | 0.95 | .802 | |
| SGOT [median, U/L] | 30 | 33 | .171 | |
| SGPT [median, U/L] | 24.5 | 29 | .404 | |
| LDH [median, U/L] | 574.5 | 698.5 | .075 | |
| Consolidation | 54 (58.1%) | 51 (57.3%) | .917 | |
| Ground glass opacity | 87 (94.6%) | 79 (88.8%) | .157 | |
| Location of lesions | Disseminated | 60 (65.3%) | 48 (53.9%) | .685 |
| Peripheral | 21 (22.8) | 12 (13.5%) | ||
| Bases | 7 (7.6%) | 19 (21.3%) | ||
| Apical | 1 (1.1%) | 7 (7.9%) | ||
| Peribronchovascular distribution | 3 (3.3%) | 3 (3.%) | ||
| Bilaterality | 88 (94.6%) | 74 (82.2%) | .009 | |
| Pleural effusion | 10 (10.8%) | 36 (40.4%) | .0001 | |
| Lymphadenopathy | 9 (9.7%) | 20 (22.7%) | .017 | |
| Calcification | 3 (3.2%) | 3 (3.4%) | 1 | |
| COVID‐19 treatment data | ||||
| O2 therapy | 91 (97.8%) | 82 (91.1%) | .06 | |
| Antibiotic therapy | 92 (98.9%) | 89 (98.9%) | 1 | |
| Steroid therapy | 12 (12.9%) | 11 (12.4%) | 1 | |
| Antiviral therapy | 56 (60.2%) | 51 (57.3%) | .690 | |
| Mechanical ventilation | 10 (10.8%) | 21 (23.6%) | .021 | |
| ICU admission | 14 (15.1%) | 22 (24.7%) | .102 | |
Note: Bold numbers show the p values which are significant at the level of p < .05.